SCHEMBL19086323

SCHEMBL19086323

COC(=O)COc1cccc(-c2ccccc2)c1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G1B P04054 2/20 0.52
LMNA P02545 5/20 0.51
L3MBTL1 Q9Y468 4/20 0.51
KDM4E B2RXH2 4/20 0.51
ALDH1A1 P00352 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
MAPT P10636 3/20 0.51
MAPK1 P28482 3/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NPC1 O15118 1/20 0.51
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
HTT P42858 3/20 0.49
USP2 O75604 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.47
KCNN4 O15554 1/20 0.46
AR P10275 1/20 0.46
GLA P06280 1/20 0.45
PAX8 Q06710 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31359444 1.00 PLA2G1B (0.52) PLA2G1BLMNAL3MBTL1KDM4EALDH1A1
SCHEMBL14327977 0.88 L3MBTL1 (0.64) LMNAL3MBTL1KDM4EALDH1A1TDP1
SCHEMBL19086322 0.86 PTGDR2 (0.61) PLA2G1BLMNAL3MBTL1KDM4EALDH1A1
SCHEMBL15518189 0.80 ALDH1A1 (0.58) LMNAL3MBTL1ALDH1A1TDP1MAPT
SCHEMBL7994085 0.79 MAPK1 (0.46) PLA2G1BLMNAL3MBTL1KDM4EALDH1A1
SCHEMBL10506317 0.79 SMN1; SMN2 (0.60) LMNAL3MBTL1KDM4EALDH1A1MAPT
SCHEMBL1706851 0.77 LMNA (0.45) LMNAL3MBTL1KDM4EALDH1A1TDP1
SCHEMBL14967298 0.77 AR (0.54) LMNAL3MBTL1KDM4EALDH1A1TDP1
SCHEMBL2904007 0.76 NOTUM (0.61) LMNAALDH1A1TDP1MAPTSMN1; SMN2
SCHEMBL29997360 0.76 PDCD1 (0.50) LMNAL3MBTL1KDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190016681-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2019-01-17 US disclosed
US-20190016681-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2019-01-17 US disclosed
WO-2017118762-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION RIJKSUNIVERSITEIT GRONINGEN (NL) 2017-07-13 WO disclosed
EP-3190103-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION Rijksuniversiteit Groningen (NL) 2017-07-12 EP disclosed
EP-3190103-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION Rijksuniversiteit Groningen (NL) 2017-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190016681-A1 INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION PDCD1, CD274, PDCD1LG2 PLA2G1B 4709/4885LMNA 4160/4885L3MBTL1 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.